GlassScriptPhysician profile
Ashli West
NPI 1942279450
$1,725.15
in general payments reported to CMS, 2019-2025
14 companies · $299 in 2025
The $299 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $14.80 · 2022: $143 · 2023: $462 · 2024: $624 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,385.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $592.08 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $365.60 | 2023-2025 | Qelbree, Qelbree |
| Pfizer INC. | $143.58 | 2019-2025 | |
| Sanofi Pasteur INC. | $112.10 | 2022-2025 | |
| Ironshore Pharmaceuticals INC. | $110.19 | 2019-2023 | Jornay Pm |
| Tris Pharma INC | $99.46 | 2019-2025 | Dyanavel Xr |
| Neos Therapeutics, LP | $96.72 | 2019-2023 | Cotempla Xr-Odt |
| Collegium Pharmaceutical, INC. | $62.67 | 2025 | Jornay Pm |
| Genentech USA, INC. | $41.37 | 2019-2023 | Xofluza |
| Merck Sharp & Dohme LLC | $33.75 | 2022-2023 | M-M-R II, Vaxelis, Vaxneuvance |
| Sobi, INC | $19.60 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.32 | 2019 | |
| Mission Pharmacal Company | $17.10 | 2019 | |
| Seqirus USA INC | $13.61 | 2024 | Flucelvax |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashli West listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.